The autocontouring technology automatically identifies and draws the boundaries of the prostate and surrounding critical structures, enabling the treatment planning software to focus radiation dose on the prostate and minimize delivering dose to the surrounding critical structures, the company said.
Euan Thomson, president and CEO of Accuray, said: “We looked at a number of companies and believe Morphormics offers the best technology to help our customers improve their productivity and patient outcomes. In keeping with Accuray’s mission to provide clinically relevant technologies, this endeavor is another example of our commitment to improving clinicians’ ability to treat prostate cancer.”
Ed Chaney, founder of Morphormics, said: “We are excited to have Accuray as our first customer and look forward to partnering with them to develop our autocontouring technology. As a medical physicist myself, I recognize the importance of extreme accuracy and precision in cancer care and believe this technology is a significant advancement in prostate cancer planning and workflow.”